BioAge Labs, Inc.
NASDAQ:BIOABiotechnology
+$0.47 today
- Market cap
- $179.59M
- Beta
- 0.95
- P/E (TTM)
- -9.7
- EPS (TTM)
- -$2.12
Volume 0.64M
Average 0.46M
BIOA Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
BioAge Labs, Inc.NASDAQ: BIOA
Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026
Selling, general & admin grows, but more slowly than its trailing trend
Q1 FY2026 selling, general & admin of $7.67M rose 13.1% year over year, behind the +27.8% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 9.6% from the prior quarter. Over 3 fiscal years it compounded at +43.3% a year.
Context
- Selling, general & admin amounted to 309.2% of revenue in FY2025.
- Selling, general & admin increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether selling, general & admin reaches the consensus estimate from 9 analysts of $9.93M (-64.3%) for the fiscal year ending Dec 2026, a slowdown from the +45.2% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $7.67M+9.6% QoQ
- Last fiscal yearDec 2025
- $27.81M+45.2% YoY
- LTMMar 2026
- $28.7M+27.8% YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 27.81M USD
- Year-over-year change
- +45.2%
- 3-year CAGR
- +43.3%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 27.81M | +45.2% |
| FY2024 | 2024-12-31 | 19.16M | +32.0% |
| FY2023 | 2023-12-31 | 14.51M | +53.6% |
| FY2022 | 2022-12-31 | 9.45M | — |
Selling, General & Admin vs competitors
How BIOA compares with its peers on the latest reported figures
- Peers report in different currencies, so selling, general & admin is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +27.8% is the highest of 9, against a peer median of -7.7%.
- Selling, general & admin amounts to 278.2% of revenue for BIOA, versus a peer median of 59.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | CA$166.84M CAD | +0.2% | +0.7% | 53.7% | |
| LTM Mar 2026 | CA$134.01M CAD | +10.1% | -9.2% | 42.9% | |
| LTM Mar 2026 | $55.88M USD | -11.2% | -10.5% | — | |
| LTM Mar 2026 | $46.76M USD | -29.2% | -11.0% | 120.9% | |
| LTM Mar 2026 | $33.33M USD | — | +8.3% | 24.7% | |
| LTM Mar 2026 | $30.28M USD | -34.0% | -12.3% | — | |
BIOABioAge Labs, Inc. | LTM Mar 2026 | $28.7M USD | +27.8% | +43.3% | 278.2% |
| LTM Mar 2026 | $28.39M USD | -5.3% | +25.8% | — | |
| LTM Mar 2026 | $27.31M USD | -10.2% | +10.9% | 1354.8% | |
| LTM Mar 2026 | $27.13M USD | -1.6% | -10.3% | 64.9% | |
| Peer median (excluding BIOA) | — | -7.7% | -9.2% | 59.3% | |
Competitors are the stored peer set for BIOA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 9M |
| Cost of Revenue | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 9M |
| Gross Margin | — | — | — | 100.0% |
| Research & Development | 30.52M | 33.89M | 59.04M | 73.97M |
| Selling, General & Admin | 9.45M | 14.51M | 19.16M | 27.81M |
| Operating Expenses | 39.97M | 48.4M | 78.19M | 101.78M |
| Depreciation & Amortization | 129K | 162K | 167K | 213K |
| EBITDA | (39.35M) | (55.9M) | (68.58M) | (79.7M) |
| EBITDA Margin | — | — | — | -886.0% |
| Operating Income | (39.97M) | (48.4M) | (78.19M) | (92.78M) |
| Operating Margin | — | — | — | -1031.5% |
| Interest Income | 465K | 2.43M | 9.63M | 13.09M |
| Interest Expense | 241K | 7.79M | 2.37M | 697K |
| Other Income / Expenses | 247K | (15.45M) | 7.09M | 12.18M |
| Income Before Tax | (39.72M) | (63.85M) | (71.11M) | (80.61M) |
| Pre-Tax Margin | — | — | — | -896.1% |
| Income Tax Expense | 0 | 0 | 0 | 0 |
| Net Income | (39.72M) | (63.85M) | (71.11M) | (80.61M) |
| Net Margin | — | — | — | -896.1% |
| EPS (Basic) | (1.16) | (1.87) | (1.98) | (2.24) |
| EPS (Diluted) | (1.16) | (1.87) | (1.98) | (2.24) |
| Weighted Avg Shares | 34.17M | 34.2M | 35.85M | 35.93M |
| Weighted Avg Shares (Diluted) | 34.17M | 34.2M | 35.85M | 35.93M |
BioAge Labs, Inc.
NASDAQ:BIOA
Intrinsic Alpha fair value
Locked
Current Price
$4.77
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.